Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.

Launched by UNIVERSITY OF MIAMI · Dec 10, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific blood test can help predict the risk of infections and other complications after a surgery called percutaneous nephrolithotomy (PCNL), which is used to remove kidney stones. The goal is to develop a system that helps doctors understand who might be at higher risk for these issues based on their blood endotoxin levels before and after the surgery.

To participate in this study, individuals must be at least 18 years old and scheduled to have the PCNL surgery at Uhealth Tower or Jackson Memorial Hospitals. They should not be currently taking medications that weaken their immune system and must have a certain level of white blood cells to be eligible. If someone joins the trial, they will have their blood tested before and after the surgery to help researchers learn more about infection risks. This information could ultimately help improve care for future patients undergoing similar procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults that is able to consent (≥ 18 years of age)
• • Scheduled to undergo PCNL at Uhealth tower and Jackson Memorial Hospitals
• • not currently immunosuppressed \[White blood count (WBC) \>= 2, not on immunosuppressive medications\]
• Exclusion Criteria:
• • unable to consent and \< 18 years of age
• • currently immunosuppressed (WBC \< 2, not on immunosuppressive medications)